Medima P300 Direct

PATIENT: ID-7890, F/72 TIME: 2026-04-17 10:34:22 UTC VITALS: HR 118 bpm (SVT), BP 88/52, RR 24, SpO2 93%, Temp 38.9°C BLOOD PANEL: Na 132 ↓, K 4.1, Glu 145 ↑, Lac 3.2 ↑, CRP 145 mg/L ↑, PCT 8.2 ng/mL ↑ WBC 18.5 ↑, Plt 98 ↓ SERS: LPS detected (E. coli, 95% confidence)

This work was funded by the Global Health Innovation Fund (Grant GH-2024-089). The authors thank the ED staff of University Hospital North and the rural health posts of Kilifi County, Kenya. medima p300

The increasing demand for rapid, accurate, and decentralized medical care has spurred the development of point-of-care (POC) devices. However, most existing systems are siloed—diagnostic devices do not communicate directly with therapeutic ones, and data integration remains a bottleneck. This paper introduces the Medima P300 , a compact, portable, multi-modal platform designed to bridge this gap. The P300 integrates (1) a 12-lead ECG and continuous vital signs monitor, (2) a laser-based flow cytometry module for complete blood counts and inflammatory markers, (3) a surface-enhanced Raman spectroscopy (SERS) chip for pathogen and biomarker identification, and (4) a microfluidic closed-loop drug delivery system. Powered by an embedded edge-AI inference engine, the device can diagnose acute coronary syndrome, sepsis, and electrolyte imbalances within 12 minutes from a single fingerstick blood sample and non-contact sensors. In therapeutic mode, the P300 administers pre-filled, algorithm-controlled medication cartridges (e.g., vasopressors, antibiotics, insulin). We present the system architecture, validation data from a pilot study (N=150), and discuss regulatory pathways. The Medima P300 represents a paradigm shift towards autonomous, interoperable POC systems for emergency rooms, ambulances, and low-resource settings. PATIENT: ID-7890, F/72 TIME: 2026-04-17 10:34:22 UTC VITALS: